Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News aTyr Pharma Inc ATYR

Healthcare Biotechnology
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause... see more

Recent & Breaking News (NDAQ:ATYR)

aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in Japan

GlobeNewswire August 11, 2020

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020

InvestmentPitch Media Video Discusses World High Life's Appointment of Ross Westbrook as Advisor for North American Operations - Video News Alert on InvestmentPitch.com

Newsfile June 26, 2020

aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

GlobeNewswire June 22, 2020

aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

GlobeNewswire June 17, 2020

aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

GlobeNewswire June 15, 2020

aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

GlobeNewswire May 20, 2020

aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19

GlobeNewswire May 12, 2020

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

GlobeNewswire May 6, 2020

aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine

GlobeNewswire May 5, 2020

aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

GlobeNewswire April 21, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of aTyr Pharma, Inc. - LIFE

ACCESSWIRE IA April 13, 2020

aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

GlobeNewswire March 26, 2020

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Government Grant to Fund Bispecific Antibody Development Platform

GlobeNewswire March 24, 2020

aTyr Pharma to Announce Fourth Quarter and Full Year End 2019 Financial Results on March 26th

GlobeNewswire March 19, 2020

Leading Cancer Researcher Dr. Arthur M. Mercurio Joins aTyr as Scientific Advisor

GlobeNewswire March 17, 2020

aTyr Pharma Announces Exercise and Closing of Over-Allotment Option in Public Offering

GlobeNewswire March 10, 2020

aTyr Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 3, 2020

aTyr Pharma Announces Publication in the Journal Cellular and Molecular Immunology

GlobeNewswire February 27, 2020

aTyr Pharma Announces Pricing of $18 million Underwritten Public Offering

GlobeNewswire February 6, 2020